HD-16: a new quality of life instrument specifically designed for insomnia

Hôtel-Dieu de Paris – Hôpitaux universitaires Paris Centre, Lutetia Parisorum, Île-de-France, France
Sleep Medicine (Impact Factor: 3.1). 06/2005; 6(3):191-8. DOI: 10.1016/j.sleep.2005.03.013
Source: PubMed

ABSTRACT To design a new quality of life (QoL) instrument specifically for insomnia.
Based on severe insomniacs' interviews, we have built a new quality of life scale that has been tested in one group of 240 severe insomniacs, in one group of 422 mild insomniacs and in one group of 391 good sleepers. Ten steps led to the construction of a specific QoL scale.
Five dimensions have been validated as both relevant and independent from each other. Sixteen items out of the 43 initially tested were retained and significantly different within the groups in each dimension. Based on the 16 items selected, we called the scale Hotel Dieu 16 (HD-16). We have therefore verified the score's specificity (correlation score of +0.36) and the reliability of the scale (Cronbach coefficient alpha=0.78).
HD-16 may be used as a focused instrument to better assess an insomniac's quality of life.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess health-related quality of life (HRQoL) associated with insomnia and prescription hypnotic use. Primary outcomes were mental component summary (MCS) and physical component summary (PCS) scores from the 12-item Short-Form Health Survey. Using multiple regression, subjects in the 2005 through 2009 Medical Expenditure Panel Survey with diagnosed insomnia were compared against those without that diagnosis. Among subjects with diagnosed insomnia, users of prescription hypnotics were compared against nonusers. Of 104,274 adults, 1.3 % (n = 1,401) had an insomnia diagnosis. Of those, 45.6 % (n = 639) used prescription hypnotics. For subjects with insomnia, mean PCS and MCS scores were 9.2 and 7.0 points lower (p < 0.001), respectively. After controlling for demographic and clinical covariates, differences remained significant (PCS:5.1; MCS:6.2; p < 0.001). Among subjects with insomnia, HRQoL scores were not different between prescription hypnotic users (n = 639) and nonusers (n = 762). Analysis by drug class revealed lower PCS scores (difference: 7.5, p < 0.001) with benzodiazepine use (n = 129) versus benzodiazepine receptor agonist use (n = 493), but the adjusted difference was not significant (difference: 3.8, p = .018). Diagnosed insomnia was associated with consistent decreases in both physical and mental HRQoL scores, regardless of whether prescription hypnotics were used. Benzodiazepine use may be associated with a further decrease in physical HRQoL scores. Although limited by its retrospective design, this study provides a first look at real-world hypnotic use outcomes at a national level. Important next steps include studies with patients serving as their own controls, and further evaluation of the sensitivity of HRQoL instruments to the effects of insomnia treatments.
    Quality of Life Research 11/2014; DOI:10.1007/s11136-014-0842-1 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pathophysiological models of insomnia invoke the concept of 24-hour hyperarousal, which could lead to symptoms and physiological findings during waking and sleep. We hypothesized that this arousal could be seen in the waking electroencephalogram (EEG) of individuals with primary insomnia (PI), and that waking EEG power would correlate with non-REM (NREM) EEG. Subjects included 50 PI and 32 good sleeper controls (GSC). Five minutes of eyes closed waking EEG were collected at subjects' usual bedtimes, followed by polysomnography (PSG) at habitual sleep times. An automated algorithm and visual editing were used to remove artifacts from waking and sleep EEGs, followed by power spectral analysis to estimate power from 0.5-32 Hz. We did not find significant differences in waking or NREM EEG spectral power of PI and GSC. Significant correlations between waking and NREM sleep power were observed across all frequency bands in the PI group and in most frequency bands in the GSC group. The absence of significant differences between groups in waking or NREM EEG power suggests that our sample was not characterized by a high degree of cortical arousal. The consistent correlations between waking and NREM EEG power suggest that, in samples with elevated NREM EEG beta activity, waking EEG power may show a similar pattern. Wu YM; Pietrone R; Cashmere JD; Begley A; Miewald JM; Germain A; Buysse DJ. EEG power during waking and NREM sleep in primary insomnia. J Clin Sleep Med 2013;9(10):1031-1037.
    Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine 01/2013; 9(10):1031-1037. DOI:10.5664/jcsm.3076 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sleep disorders and insomnia at the first raw are unsufficiently diagnosed and treated in primary care. Poor sleep is often not considered as a disease but as a common symptom which does not concern the doctors. However, due to the high number of patients, insomnia has a real impact on economics and on quality of life. The goal of this paper is to review the available litterature on the economical impact of insomnia.
    Médecine du Sommeil 12/2008; 5(18). DOI:10.1016/S1769-4493(08)70188-2